Potent vs moderate‐potency topical corticosteroid
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
- Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 99 participantsVery low